According to the amyloid/tau/neurodegeneration (ATN) classification, MCI with Alzheimer’s disease (AD) biomarkers is defined as a clinical stage of Alzheimer’s continuum [1]. The gene discussed is MAPT; the disease is Alzheimer disease.